Apimeds Pharmaceuticals US, Inc.
Ticker: 1894525
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q3 FY26 | Q2 FY26 |
|---|---|---|
| INCOME | ||
| Revenue | 2.90+935.7% | 0.28 |
| Total Income | 2.90+935.7% | 0.28 |
| EXPENSES | ||
| Expenditure | 0.87-95.7% | 20.46 |
| PROFIT | ||
| Net Profit | 33.65+266.8% | -20.17 |
| KEY METRICS | ||
| OPM % | 70.03% | — |
| NPM % | 100.00%+200.00pp | -100.00% |
| EPS | 19.13 | — |
Corporate Events
Board MeetingAPUS
202629Sep
Board Meeting
Erick Frim resigned as Interim Chief Financial Officer and E…
SEC Filing ↗ Board MeetingAPUS
202610Sep
Board Meeting
The Board composition has been restructured following an ame…
SEC Filing ↗ Board MeetingAPUS
20265Aug
Board Meeting
Appointment of Dr. Christopher Kim as Chief Scientific Offic…
SEC Filing ↗ Board MeetingAPUS
20264May
Board Meeting
Appointment of Sungjoon Chae as Co-Chief Executive Officer …
SEC Filing ↗ Board MeetingAPUS
202624Apr
Board Meeting
Apimeds Pharmaceuticals US, Inc. entered into a Confidential…
SEC Filing ↗ Board MeetingAPUS
202620Mar
Board Meeting
Clarification that previously reported purported removals of…
SEC Filing ↗